Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.4 USD | -4.10% | -21.75% | -60.92% |
Apr. 30 | Medifast Shares Drop as Q1 Adjusted Earnings, Revenue Decline; Sets Q2 Guidance | MT |
Apr. 30 | Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The stock, which is currently worth 2024 to 0.18 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The firm trades with high earnings multiples: 31.64 times its 2024 earnings per share.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-60.92% | 294M | C- | ||
+13.21% | 8.15B | D+ | ||
-0.47% | 7.23B | C- | ||
+12.30% | 6.65B | - | ||
-6.99% | 3.72B | D | ||
-7.75% | 3.64B | B- | ||
-4.78% | 1.31B | - | - | |
+12.61% | 972M | - | ||
-43.94% | 863M | B+ | ||
-14.65% | 799M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.